Nightfood Holdings Inc. (OTCQB: NGTF), doing business as TechForce Robotics, has announced a joint development, manufacturing and licensing agreement with Oncotelic Therapeutics (OTCQB: OTLC) to co-develop AI-enhanced, GMP-compliant robotic systems for pharmaceutical manufacturing and laboratory automation. The collaboration combines TechForce’s robotics engineering with Oncotelic’s AI-driven pharmaceutical technologies to target improved efficiency, compliance and scalability in biopharma production.
The partnership represents a strategic expansion for TechForce Robotics into regulated healthcare markets, leveraging Oncotelic CEO Dr. Vuong Trieu’s experience in oncology, drug development and AI-enabled innovation. According to the announcement, the companies aim to address critical needs in pharmaceutical manufacturing, where precision, compliance and scalability are paramount.
“This collaboration with Oncotelic marks a significant milestone for TechForce Robotics as we expand our AI-enhanced automation solutions into the pharmaceutical and biotech sectors,” said a company representative. “By combining our robotics expertise with Oncotelic’s deep domain knowledge in AI-driven drug development, we are well-positioned to deliver transformative solutions that enhance manufacturing efficiency and regulatory compliance.”
TechForce Robotics, a wholly owned subsidiary of Nightfood Holdings, is an AI-enhanced service-robotics and automation company focused on developing, deploying and scaling autonomous robotic solutions for hospitality, foodservice and commercial applications. The company’s vertically integrated platform combines proprietary robotics technology, real-world operating environments and scalable manufacturing to accelerate automation adoption across multiple industries.
Nightfood Holdings is an emerging robotics company focused on deploying AI-powered automation across multiple industries. Hospitality is the company’s initial sector of entry, where its Robotics-as-a-Service (RaaS) platform addresses repetitive, labor-intensive and operationally constrained tasks. The long-term vision includes expansion into additional verticals requiring similar automation solutions.
Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on developing AI-driven therapies for oncology and other diseases. The company’s expertise in AI-enabled drug development and manufacturing processes will be critical to the partnership’s success.
For more information about Nightfood Holdings, visit the company’s newsroom at http://ibn.fm/NGTF. The full press release is available at https://ibn.fm/aPEgr.
